A5033502648- Pancreatic and Hepatic Oncology Research
- Pancreatitis Pathology and Treatment
- Neuroendocrine Tumor Research Advances
- Peptidase Inhibition and Analysis
- Renal cell carcinoma treatment
- Cancer Genomics and Diagnostics
- Neuropeptides and Animal Physiology
- Protease and Inhibitor Mechanisms
- Orthopedic Surgery and Rehabilitation
- Antimicrobial Peptides and Activities
- Nutrition and Health in Aging
- Myasthenia Gravis and Thymoma
- Cardiac Structural Anomalies and Repair
- Gastrointestinal disorders and treatments
- Gallbladder and Bile Duct Disorders
- Colorectal Cancer Surgical Treatments
- Travel-related health issues
- Surgical Simulation and Training
- Electronic Health Records Systems
- Economic and Financial Impacts of Cancer
- Genetics, Bioinformatics, and Biomedical Research
- Artificial Intelligence in Healthcare and Education
- Parasitic infections in humans and animals
- Clinical Reasoning and Diagnostic Skills
- Lymphatic Disorders and Treatments
University Hospital Heidelberg
2014-2025
Heidelberg University
2015-2025
Evangelisches Krankenhaus Düsseldorf
2018
German Cancer Research Center
2018
EES Research (United Kingdom)
2018
Research Network (United States)
2018
Dirección de Investigación y Desarrollo
2018
Chirurgische Universitätsklinik Heidelberg
2011-2017
Rhön-Klinikum
2011-2012
Abstract The characteristic desmoplastic stroma of pancreatic ductal adenocarcinoma (PDAC) is a key contributor to its lethality. This stromal microenvironment populated by cancer-associated fibroblasts (CAFs) that interact with cancer cells drive progression and chemo-resistance. Research has focused on CAFs in the primary tumour but not metastases, calling into question role analogous metastasis-associated (MAFs). We infer MAFs murine hepatic metastases following untargeted treatment...
Pancreatic intraductal papillary mucinous neoplasms (IPMNs) are grossly visible (typically > 5 mm) epithelial of mucin-producing cells, arising in the main pancreatic duct or its branches. According to current 2-tiered grading scheme, these lesions categorized as having either low-grade (LG) dysplasia, which has a benign prognosis, high-grade (HG) formally represents carcinoma situ and thus can transform ductal adenocarcinoma (PDAC). Because both entities require different treatments...
Abstract Structured patient data play a key role in all types of clinical research. They are often collected study databases for research purposes. In order to describe characteristics next-generation database and assess the feasibility its implementation proof-of-concept German university hospital was performed. Key identified include FAIR access electronic case report forms (eCRF), regulatory compliant Electronic Data Capture (EDC), an EDC with health record (EHR) integration, scalable...
Background: The invisible fluid leaking from a partially resected pancreas is associated with complications including postoperative pancreatic fistula (POPF), calling for strategies to visualize intraoperative leakage. This single-arm, monocentric trial aims evaluate the usefulness and safety of SmartPAN, hydrogel that reacts alkali fluids by changing color thus enables surgeon take immediate action close Methods: Patients awaiting partial resection any indication were recruited receive...
Chyle leak is a well known but poorly characterized complication after pancreatic surgery. Available data on incidence, risk factors and clinical significance of chyle are highly heterogeneous.For this cohort study all patients who underwent surgery between January 2008 December 2012 were identified from prospective database. was defined as any drainage output with triglyceride content 110 mg/dl or more. Risk for assessed by univariable multivariable analyses. The relevance evaluated using...
Guidelines do not recommend resection surgery for oligometastatic pancreatic ductal adenocarcinoma (PDAC). However, reports in small samples of selected patients suggest that extends survival. Thus, this study aims to gather evidence the benefits cancer-directed (CDS) by analyzing a national cohort and identifying prognostic factors aid selection candidates CDS or recruitment into experimental trials. Data with PDAC hepatic metastasis were extracted from population-based Surveillance,...
Pancreatic ductal adenocarcinoma (PDAC) may arise from intraductal papillary mucinous neoplasms (IPMN) with malignant transformation, but a significant portion of IPMN remains to show benign behavior. Therefore, it is important differentiate between and lesions undergoing transformation. However, nonoperative differentiation by ultrasound, CT, MRI, carbohydrate antigen 19-9 (CA19-9) still unsatisfactory. Here, we assessed the clinical feasibility additional assessment malignancy PET using...
Rare truncating BRCA2 K3326X (rs11571833) and pathogenic CHEK2 I157T (rs17879961) variants have previously been implicated in familial pancreatic ductal adenocarcinoma (PDAC), but not sporadic cases. The effect of both mutations important DNA repair genes on PDAC risk may shed light the genetic architecture this disease. Both were genotyped germline from 2,935 cases 5,626 control subjects within PANcreatic Disease ReseArch (PANDoRA) consortium. Risk estimates evaluated using multivariate...
Abstract Positron emission tomography with 68 Gallium ( Ga) labeled inhibitors of fibroblast activation protein Ga-FAPI-PET) is a promising imaging technique for patients recurrent pancreatic ductal adenocarcinomas (PDAC). To date, it not clear if different acquisition timepoints Ga-FAPI-PET may result in comparable information and repetitive add diagnostic value to single timepoint PDAC. Here we analyzed retrospectively early (20 min p.i.) late (60 using FAPI-46 33 possible recurrence PDAC...
Postoperative pancreatic fistula is a major surgical complication that can follow resection. develop as consequence of leaking fluid, which calls for an intraoperative indicator leakage. But suitable indicators leakage have yet to be found. This study details the evidence-based development and early efficacy assessments novel (SmartPAN), following IDEAL framework product development. We developed 41 SmartPAN prototypes by combining fluid with polysaccharide-microsphere matrix. The were...
Objective: Whether a Blumgart anastomosis (BA) is superior to Cattell-Warren (CWA) in terms of postoperative pancreatic fistula (POPF) following pancreatoduodenectomy. Importance: Complications driven by POPF cancer resection may hinder adjuvant therapy, shortening survival. BA reduce complications compared CWA, improving the use therapy and prolonging Methods: A multicenter double-blind, controlled trial patients undergoing for suspected head cancer, randomized during surgery or stratified...
Middle segment-preserving pancreatectomy (MPP) can treat multilocular diseases in the pancreatic head and tail while avoiding impairments caused by total (TP). We conducted a systematic literature review of MPP cases collected individual patient data (IPD). patients (N = 29) were analyzed compared to group TP 14) terms clinical baseline characteristics, intraoperative course, postoperative outcomes. also limited survival analysis following MPP. Pancreatic functionality was better preserved...
Pancreatic surgery is complicated by untreated fluid leakage, but no tenable techniques exist to detect and close leakage sites during surgery. A novel hydrogel called SmartPAN has been developed meet this need here assessed for safety before trials on human patients. First, resazurin assays were used test the cytotoxic effects of SmartPAN's active bromothymol blue (BTB) indicator its solution phosphate-buffered saline (PBS) normal (HPDE: pancreatic duct epithelial) or carcinomic (FAMPAC)...
Neoadjuvant therapy (NT) for advanced PDAC is an emerging concept, affecting both stroma and tumor. The Activated Stroma Index (ASI; ratio of activated cancer-associated fibroblasts (CAF) to collagen deposition) a prognostic marker in upfront resected pancreatic adenocarcinoma (PDAC). We assessed ASI its relevance after NT. Tissue from resection specimens n = 48 patients neoadjuvant chemotherapy with FOLFIRINOX (FOL; 31), gemcitabine + nab-paclitaxel (GEM; 7) or combination treatment (COMB;...